Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics

被引：23

作者：

Dwivedi, Mitesh ^{[1
]}

Tiwari, Sanjay ^{[2
]}

Kemp, E. Helen ^{[3
]}

Begum, Rasheedunnisa ^{[4
]}

机构：

[1] Uka Tarsadia Univ, Fac Sci, C G Bhakta Inst Biotechnol, Surat 394350, Gujarat, India

[2] Natl Inst Pharmaceut Educ & Res NIPER, Dept Pharmaceut, Lucknow 226002, Uttar Pradesh, India

[3] Univ Sheffield, Fac Med, Dept Oncol & Metab, Dent & Hlth, Sheffield S10, England

[4] Maharaja Sayajirao Univ Baroda, Fac Sci, Dept Biochem, Vadodara 390002, Gujarat, India

来源：

HELIYON | 2022年 / 8卷 / 08期

关键词：

Anti-cancer immunity; Cancer; CD8(+) T cells; CD4(+) T cells; Regulatory T cells; Tumor-infiltrating lymphocytes; TRANSCRIPTION FACTOR FOXP3; DRAINING LYMPH-NODES; PERIPHERAL-BLOOD; TUMOR-CELLS; IN-VITRO; HEPATOCELLULAR-CARCINOMA; TGF-BETA; INCREASED POPULATIONS; MEDIATED SUPPRESSION; COLORECTAL-CARCINOMA;

D O I：

10.1016/j.heliyon.2022.e10450

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Regulatory T cells (Tregs) play an essential role in maintaining immune tolerance and suppressing inflammation. However, Tregs present major hurdle in eliciting potent anti-cancer immune responses. Therefore, curbing the activity of Tregs represents a novel and efficient way towards successful immunotherapy of cancer. Moreover, there is an emerging interest in harnessing Treg-based strategies for augmenting anti-cancer immunity in different types of the disease. This review summarises the crucial mechanisms of Tregs' mediated suppression of anti-cancer immunity and strategies to suppress or to alter such Tregs to improve the immune response against tu-mors. Highlighting important clinical studies, the review also describes current Treg-based therapeutic in-terventions in cancer, and discusses Treg-suppression by molecular targeting, which may emerge as an effective cancer immunotherapy and as an alternative to detrimental chemotherapeutic agents.

引用

页数：12

共 203 条

[1] Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy [J].

Ahmad, Shamim ;

Abu-Eid, Rasha ;

Shrimali, Rajeev ;

Webb, Mason ;

Verma, Vivek ;

Doroodchi, Atbin ;

Berrong, Zuzana ;

Samara, Raed ;

Rodriguez, Paulo C. ;

Mkrtichyan, Mikayel ;

Khleif, Samir N. .

CANCER RESEARCH, 2017, 77 (08) :1892-1904

[2] Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer [J].

Ali, Khaled ;

Soond, Dalya R. ;

Pineiro, Roberto ;

Hagemann, Thorsten ;

Pearce, Wayne ;

Lim, Ee Lyn ;

Bouabe, Hicham ;

Scudamore, Cheryl L. ;

Hancox, Timothy ;

Maecker, Heather ;

Friedman, Lori ;

Turner, Martin ;

Okkenhaug, Klaus ;

Vanhaesebroeck, Bart .

NATURE, 2014, 510 (7505) :407-+

[3] Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells [J].

Alvaro, T ;

Lejeune, M ;

Salvadó, MT ;

Bosch, R ;

García, JF ;

Jaén, J ;

Banham, AH ;

Roncador, G ;

Montalbán, C ;

Piris, MA .

CLINICAL CANCER RESEARCH, 2005, 11 (04) :1467-1473

[4] Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments [J].

Angelin, Alessia ;

Gil-de-Gomez, Luis ;

Dahiya, Satinder ;

Jiao, Jing ;

Guo, Lili ;

Levine, Matthew H. ;

Wang, Zhonglin ;

Quinn, William J., III ;

Kopinski, Piotr K. ;

Wang, Liqing ;

Akimova, Tatiana ;

Liu, Yujie ;

Bhatti, Tricia R. ;

Han, Rongxiang ;

Laskin, Benjamin L. ;

Baur, Joseph A. ;

Blair, Ian A. ;

Wallace, Douglas C. ;

Hancock, Wayne W. ;

Beier, Ulf H. .

CELL METABOLISM, 2017, 25 (06) :1282-+

[5]

[Anonymous], 2012, J CANC RES THER

[6] CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2 [J].

Antony, PA ;

Restifo, NP .

JOURNAL OF IMMUNOTHERAPY, 2005, 28 (02) :120-128

[7] Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes [J].

Audia, S. ;

Nicolas, A. ;

Cathelin, D. ;

Larmonier, N. ;

Ferrand, C. ;

Foucher, P. ;

Fanton, A. ;

Bergoin, E. ;

Maynadie, M. ;

Arnould, L. ;

Bateman, A. ;

Lorcerie, B. ;

Solary, E. ;

Chauffert, B. ;

Bonnotte, B. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 150 (03) :523-530

[8]

AWWAD M, 1988, IMMUNOLOGY, V65, P87

[9]

Azuma T, 2003, CANCER RES, V63, P4516

[10] Ex-Th17 (Nonclassical Th1) Cells Are Functionally Distinct from Classical Th1 and Th17 Cells and Are Not Constrained by Regulatory T Cells [J].

Basdeo, Sharee A. ;

Cluxton, Deborah ;

Sulaimani, Jamal ;

Moran, Barry ;

Canavan, Mary ;

Orr, Carl ;

Veale, Douglas J. ;

Fearon, Ursula ;

Fletcher, Jean M. .

JOURNAL OF IMMUNOLOGY, 2017, 198 (06) :2249-2259

← 1 2 3 4 5 6 7 8 9 10 →